The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer

Hickey, Theresa E, Selth, Luke A, Chia, Kee Ming, Laven-Law, Geraldine, Milioli, Heloisa H, Roden, Daniel, Jindal, Shalini, Hui, Mun, Finlay-Schultz, Jessica, Ebrahimie, Esmaeil
et al (show 14 more authors) (2021) The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. NATURE MEDICINE, 27 (2). 310-+.

[thumbnail of Hickey et al. 2021.pdf] Text
Hickey et al. 2021.pdf - Author Accepted Manuscript

Download (113MB) | Preview


The role of the androgen receptor (AR) in estrogen receptor (ER)-α-positive breast cancer is controversial, constraining implementation of AR-directed therapies. Using a diverse, clinically relevant panel of cell-line and patient-derived models, we demonstrate that AR activation, not suppression, exerts potent antitumor activity in multiple disease contexts, including resistance to standard-of-care ER and CDK4/6 inhibitors. Notably, AR agonists combined with standard-of-care agents enhanced therapeutic responses. Mechanistically, agonist activation of AR altered the genomic distribution of ER and essential co-activators (p300, SRC-3), resulting in repression of ER-regulated cell cycle genes and upregulation of AR target genes, including known tumor suppressors. A gene signature of AR activity positively predicted disease survival in multiple clinical ER-positive breast cancer cohorts. These findings provide unambiguous evidence that AR has a tumor suppressor role in ER-positive breast cancer and support AR agonism as the optimal AR-directed treatment strategy, revealing a rational therapeutic opportunity.

Item Type: Article
Uncontrolled Keywords: Cell Line, Tumor, Humans, Breast Neoplasms, Receptors, Androgen, Estrogen Receptor alpha, Androgens, Signal Transduction, Cell Proliferation, Female, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Nuclear Receptor Coactivator 3, MCF-7 Cells
Depositing User: Symplectic Admin
Date Deposited: 11 Feb 2021 10:10
Last Modified: 24 Mar 2023 12:20
DOI: 10.1038/s41591-020-01168-7
Related URLs: